-- Dow AgroSciences has the option to exercise a commercial license for
the use of our ZFP technology in plant agriculture in the second half
-- The Phase 2 trial that Sangamo plans to initiate in the first quarter
of 2008 evaluating the mobilization of aldehyde bright stem cells in
subjects with diabetic neuropathy after treatment with the SB-509.
-- Plans for a Phase 2 trial of SB-509 for the treatment of ALS will also
be outlined at the briefing. Sangamo expects to initiate this trial in
the first half of 2008.
-- Plans to initiate a Phase 1 trial of a ZFP Therapeutic to treat
glioblastoma in the first half of 2008 and a Phase 1 trial for a ZFP
Therapeutic to treat HIV infection in the second half of 2008.
-- Sangamo expects to report data from the Phase 1 clinical programs in
critical limb ischemia, the severe form of peripheral artery disease in
-- Sangamo estimates that it expects to end 2008 with approximately $55M
in cash and cash equivalents, based on current expense projections and
expected progress in existing corporate relationships.
The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website until December 20, 2007 and is available at via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations."
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and
modification. The most advanced ZFP Therapeutic(TM) development program is
currently in Phase 2 clinical trials for evaluation of safety and clinical
effect in patients with diabetic neuropathy. Phase 1 clinical trials are
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved